Patients with tumor mutations in the erythroblastic leukemia viral oncogene homolog (ErbB) family, including EGFR and ErbB2, had a significantly shorter disease-free survival than those with wild-type EGFR or ErbB2. The gene discussed is EGFR; the disease is neoplasm.